Trevi Therapeutics Inc [TRVI] stock prices are up 1.36% to $2.98 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TRVI shares have gain 10.37% over the last week, with a monthly amount glided 17.32%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on June 13, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $7. Previously, B. Riley Securities started tracking the stock with Buy rating on April 12, 2023, and set its price target to $6. On November 22, 2022, SVB Leerink initiated with a Outperform rating and assigned a price target of $6 on the stock. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $14 on June 03, 2019. Stifel initiated its recommendation with a Buy and recommended $20 as its price target on June 03, 2019. Needham started tracking with a Buy rating for this stock on June 03, 2019, and assigned it a price target of $18. In a note dated June 03, 2019, BMO Capital Markets initiated an Outperform rating and provided a target price of $15 on this stock.
The stock price of Trevi Therapeutics Inc [TRVI] has been fluctuating between $0.97 and $4.00 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $2.98 at the most recent close of the market. An investor can expect a potential return of 302.68% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at 0.21% with Operating Profit Margin at -217.42%, Pretax Profit Margin comes in at -190.9%, and Net Profit Margin reading is -190.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.4 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.84 points at the first support level, and at 2.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.16, and for the 2nd resistance point, it is at 3.33.
Ratios To Look Out For
It’s worth pointing out that Trevi Therapeutics Inc [NASDAQ:TRVI]’s Current Ratio is 14.55. On the other hand, the Quick Ratio is 14.55, and the Cash Ratio is 2.62.
Transactions by insiders
Recent insider trading involved SCIASCIA THOMAS, Chief Scientific Officer, that happened on May 29 ’24 when 53368.0 shares were sold. Chief Financial Officer, Delfini Lisa completed a deal on May 22 ’24 to sell 4350.0 shares. Meanwhile, President & CEO GOOD JENNIFER L sold 25037.0 shares on May 20 ’24.
